Celularity Inc (CELU) stock
CELUNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.57−0.05 (-7.75%)
Close on Nov 17, 2026Market cap $18.53MP/E –Yield –
Celularity operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Celularity's operating cash flow for the twelve months ending Jun 30, 2026 was -$8.92M. For fiscal 2025 it was -$13.25M. The highest annual figure on record is -$1.10M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$13.25M | – |
| FY2024 | Dec 31, 2024 | -$6.40M | – |
| FY2023 | Dec 31, 2023 | -$38.69M | – |
| FY2022 | Dec 31, 2022 | -$137.88M | – |
| FY2021 | Dec 31, 2021 | -$110.10M | – |
| FY2020 | Dec 31, 2020 | -$63.19M | – |
| FY2019 | Dec 31, 2019 | -$1.10M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$1.11M | – |
| Q1 FY2026 | Mar 31, 2026 | $1.45M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.10M | -420.1% |
| Q3 FY2025 | Sep 30, 2025 | -$4.16M | – |
| Q2 FY2025 | Jun 30, 2025 | -$999.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$2.99M | – |
| Q4 FY2024 | Dec 31, 2024 | $1.59M | – |
| Q3 FY2024 | Sep 30, 2024 | -$144.00K | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.40M | – |
| Q4 FY2023 | Dec 31, 2023 | -$4.34M | – |
| Q3 FY2023 | Sep 30, 2023 | -$8.32M | – |
| Q2 FY2023 | Jun 30, 2023 | -$11.03M | – |
| Q1 FY2023 | Mar 31, 2023 | -$15.00M | – |
| Q4 FY2022 | Dec 31, 2022 | -$29.59M | – |
| Q3 FY2022 | Sep 30, 2022 | -$37.72M | – |
| Q2 FY2022 | Jun 30, 2022 | -$36.32M | – |
| Q1 FY2022 | Mar 31, 2022 | -$34.25M | – |
| Q4 FY2021 | Dec 31, 2021 | -$32.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$34.77M | – |
| Q2 FY2021 | Jun 30, 2021 | -$18.20M | – |
| Q1 FY2021 | Mar 31, 2021 | -$25.08M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.83M | – |
| Q3 FY2020 | Sep 30, 2020 | -$45.59M | – |
| Q2 FY2020 | Jun 30, 2020 | -$224.43K | – |
| Q1 FY2020 | Mar 31, 2020 | -$549.58K | – |
| Q4 FY2019 | Dec 31, 2019 | -$223.80K | – |
| Q3 FY2019 | Sep 30, 2019 | -$679.22K | – |
| Q2 FY2019 | Jun 30, 2019 | -$194.13K | – |
| Q1 FY2019 | Mar 31, 2019 | -$676 | – |
See a number that looks wrong?